IMMVIRX

ImmVirX is an Australian company founded in 2019 with a mission to improve outcomes for patients with cancer types in which immunotherapy treatments have limited effect... ImmVirX was founded in July 2019 by the team from Viralytics, a clinical-stage ASX-listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million. We are developing proprietary bio-selected RNA viruses with the capacity to selectively infect and kill cancer cells while also inducing tumour inflammation and achieving immune cell infiltration - potentially leading to the generation of specific innate and adaptive immune responses against cancer cells... ImmVirX is developing novel oncolytic viruses to create powerful new cancer immunotherapy combinations

Also known as: ImmVirX Pty Ltd

Primary location: Heights Australia